Binding of carbamyl-platelet-activating factor to the raji lymphoblast platelet-activating factor receptor

Jeffrey Travers, Qian Li, Howard Sprecher, Richard H. Fertel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Carbamyl-platelet-activating factor (1-hexadecyl-2-N-methylcarbamyl-glycero-3-phosphocholine; CPAF) is an analog of platelet-activating factor (PAF) containing an N-methylcarbamyl moiety at the sn-2 position. CPAF was tested for effects on the Raji lymphoblast PAF receptor. Binding studies conducted at 4°C demonstrated specific binding that reached saturation within 60-80 min. Scatchard analysis of CPAF binding data revealed a single class of CPAF binding sites (14,800/cell) with a K = 2.9 ± 0.9 nM. Competition binding studies with PAF indicated that CPAF has about one-third the potency of native PAF. Unlike PAF, however, CPAF was not significantly metabolized by Raji lymphoblasts at 37°C. CPAF was shown to have PAF-agonistic qualities, since 100 pM to 1 μM CPAF increased free intracellular calcium in a dose-dependent manner. The structurally dissimilar PAF receptor antagonists CV-6209 and alprazolam inhibited the CPAF-induced calcium changes at doses that compared with CPAF binding. Treatment of Raji lymphoblasts with PAF or CPAF (10 pM - 1 μM) did not affect spontaneous proliferation, suggesting that the PAF receptor is not involved in the proliferation process in this cell line. These studies demonstrate that CPAF is a metabolically stable lymphoblast PAF receptor agonist that may provide a useful tool in the further elucidation of the role of PAF in lymphocyte function.

Original languageEnglish (US)
Pages (from-to)515-523
Number of pages9
JournalInternational Journal of Immunopharmacology
Volume14
Issue number4
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Platelet Activating Factor
Alprazolam
Calcium
Phosphorylcholine
platelet activating factor receptor
1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine
Binding Sites
Lymphocytes
Cell Line

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Binding of carbamyl-platelet-activating factor to the raji lymphoblast platelet-activating factor receptor. / Travers, Jeffrey; Li, Qian; Sprecher, Howard; Fertel, Richard H.

In: International Journal of Immunopharmacology, Vol. 14, No. 4, 1992, p. 515-523.

Research output: Contribution to journalArticle

@article{3dd3f52062a047b281758c422a344203,
title = "Binding of carbamyl-platelet-activating factor to the raji lymphoblast platelet-activating factor receptor",
abstract = "Carbamyl-platelet-activating factor (1-hexadecyl-2-N-methylcarbamyl-glycero-3-phosphocholine; CPAF) is an analog of platelet-activating factor (PAF) containing an N-methylcarbamyl moiety at the sn-2 position. CPAF was tested for effects on the Raji lymphoblast PAF receptor. Binding studies conducted at 4°C demonstrated specific binding that reached saturation within 60-80 min. Scatchard analysis of CPAF binding data revealed a single class of CPAF binding sites (14,800/cell) with a K = 2.9 ± 0.9 nM. Competition binding studies with PAF indicated that CPAF has about one-third the potency of native PAF. Unlike PAF, however, CPAF was not significantly metabolized by Raji lymphoblasts at 37°C. CPAF was shown to have PAF-agonistic qualities, since 100 pM to 1 μM CPAF increased free intracellular calcium in a dose-dependent manner. The structurally dissimilar PAF receptor antagonists CV-6209 and alprazolam inhibited the CPAF-induced calcium changes at doses that compared with CPAF binding. Treatment of Raji lymphoblasts with PAF or CPAF (10 pM - 1 μM) did not affect spontaneous proliferation, suggesting that the PAF receptor is not involved in the proliferation process in this cell line. These studies demonstrate that CPAF is a metabolically stable lymphoblast PAF receptor agonist that may provide a useful tool in the further elucidation of the role of PAF in lymphocyte function.",
author = "Jeffrey Travers and Qian Li and Howard Sprecher and Fertel, {Richard H.}",
year = "1992",
doi = "10.1016/0192-0561(92)90112-X",
language = "English (US)",
volume = "14",
pages = "515--523",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Binding of carbamyl-platelet-activating factor to the raji lymphoblast platelet-activating factor receptor

AU - Travers, Jeffrey

AU - Li, Qian

AU - Sprecher, Howard

AU - Fertel, Richard H.

PY - 1992

Y1 - 1992

N2 - Carbamyl-platelet-activating factor (1-hexadecyl-2-N-methylcarbamyl-glycero-3-phosphocholine; CPAF) is an analog of platelet-activating factor (PAF) containing an N-methylcarbamyl moiety at the sn-2 position. CPAF was tested for effects on the Raji lymphoblast PAF receptor. Binding studies conducted at 4°C demonstrated specific binding that reached saturation within 60-80 min. Scatchard analysis of CPAF binding data revealed a single class of CPAF binding sites (14,800/cell) with a K = 2.9 ± 0.9 nM. Competition binding studies with PAF indicated that CPAF has about one-third the potency of native PAF. Unlike PAF, however, CPAF was not significantly metabolized by Raji lymphoblasts at 37°C. CPAF was shown to have PAF-agonistic qualities, since 100 pM to 1 μM CPAF increased free intracellular calcium in a dose-dependent manner. The structurally dissimilar PAF receptor antagonists CV-6209 and alprazolam inhibited the CPAF-induced calcium changes at doses that compared with CPAF binding. Treatment of Raji lymphoblasts with PAF or CPAF (10 pM - 1 μM) did not affect spontaneous proliferation, suggesting that the PAF receptor is not involved in the proliferation process in this cell line. These studies demonstrate that CPAF is a metabolically stable lymphoblast PAF receptor agonist that may provide a useful tool in the further elucidation of the role of PAF in lymphocyte function.

AB - Carbamyl-platelet-activating factor (1-hexadecyl-2-N-methylcarbamyl-glycero-3-phosphocholine; CPAF) is an analog of platelet-activating factor (PAF) containing an N-methylcarbamyl moiety at the sn-2 position. CPAF was tested for effects on the Raji lymphoblast PAF receptor. Binding studies conducted at 4°C demonstrated specific binding that reached saturation within 60-80 min. Scatchard analysis of CPAF binding data revealed a single class of CPAF binding sites (14,800/cell) with a K = 2.9 ± 0.9 nM. Competition binding studies with PAF indicated that CPAF has about one-third the potency of native PAF. Unlike PAF, however, CPAF was not significantly metabolized by Raji lymphoblasts at 37°C. CPAF was shown to have PAF-agonistic qualities, since 100 pM to 1 μM CPAF increased free intracellular calcium in a dose-dependent manner. The structurally dissimilar PAF receptor antagonists CV-6209 and alprazolam inhibited the CPAF-induced calcium changes at doses that compared with CPAF binding. Treatment of Raji lymphoblasts with PAF or CPAF (10 pM - 1 μM) did not affect spontaneous proliferation, suggesting that the PAF receptor is not involved in the proliferation process in this cell line. These studies demonstrate that CPAF is a metabolically stable lymphoblast PAF receptor agonist that may provide a useful tool in the further elucidation of the role of PAF in lymphocyte function.

UR - http://www.scopus.com/inward/record.url?scp=0026642986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026642986&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(92)90112-X

DO - 10.1016/0192-0561(92)90112-X

M3 - Article

C2 - 1325953

AN - SCOPUS:0026642986

VL - 14

SP - 515

EP - 523

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 4

ER -